by Truveta Staff | Mar 22, 2023 | News
Today, Truveta and Alpine Immune Sciences, Inc. announced a strategic partnership to help accelerate clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory...
by Terry Myerson | Mar 1, 2023 | News
Today we are excited to announce that we’ve expanded the de-identified data in Truveta Studio to include 28 additional social drivers of health (SDOH) attributes – such as education, income, housing stability, social support, and more – for nearly 80 million...
by Truveta Staff | Feb 15, 2023 | News, Research
The United States is one of the most dangerous high-income countries in which to give birth. Nearly every negative maternal health outcome impacts women of color more than white women. This February, in honor of Heart Health Month and Black History Month, Truveta...
by Lisa Gurry, COO | Jan 31, 2023 | News
Last week, I joined a few of my fellow Truvetans, including our CEO Terry Myerson, pictured above, at the Precision Medicine World Conference in Santa Clara, CA for a few days of meetings, sessions, and great discussions. I personally find it so valuable to connect...
by Truveta Staff | Jan 18, 2023 | News, Research
In November, Truveta Research shared their findings on racial disparities in treatment and hospitalization during different periods of time of the COVID-19 pandemic. Now, the peer-reviewed paper, “Racial inequality in COVID treatment and in-hospital length of...
by Truveta Staff | Dec 13, 2022 | News
Each month, we spotlight one of the many great leaders from the 25 member health systems that make up Truveta and help advance our mission of saving lives with data. We’ll share their perspectives on the future of medicine, the changing role of technology in...
